Candidiasis - Pipeline Review, H2 2020

August 2020 | 225 pages | ID: C1A9F76F89FEN
Global Markets Direct

Abstracts

Candidiasis - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H2 2020, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 5, 3, 32, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Candidiasis - Overview
Candidiasis - Therapeutics Development
Candidiasis - Therapeutics Assessment
Candidiasis - Companies Involved in Therapeutics Development
Candidiasis - Drug Profiles
Candidiasis - Dormant Projects
Candidiasis - Discontinued Products
Candidiasis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Candidiasis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Companies, H2 2020 (Contd..3), H2 2020
Products under Development by Universities/Institutes, H2 2020
Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Candidiasis - Pipeline by Acea Biotech Inc, H2 2020
Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2020
Candidiasis - Pipeline by Autoimmune Technologies LLC, H2 2020
Candidiasis - Pipeline by Bakker Medical Srl, H2 2020
Candidiasis - Dormant Projects, H2 2020
Candidiasis - Dormant Projects, H2 2020 (Contd..1), H2 2020
Candidiasis - Dormant Projects, H2 2020 (Contd..2), H2 2020
Candidiasis - Dormant Projects, H2 2020 (Contd..3), H2 2020
Candidiasis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Candidiasis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Autoimmune Technologies LLC
Bakker Medical Srl
Beta Pharma Inc
Biokawthar Technologies SAS
Biomendics LLC
Biosergen AS
Cellix Bio Pvt Ltd
Cidara Therapeutics Inc
CSA Biotechnologies LLC
CSPC Pharmaceutical Group Ltd
Destiny Pharma Plc
Fox Chase Chemical Diversity Center Inc
FUJIFILM Toyama Chemical Co Ltd
General Biologicals Corp
Grupo Ferrer Internacional SA
Helix BioMedix Inc
Hennepin Life Sciences LLC
iCo Therapeutics Inc
iNtRON Biotechnology Inc
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Mycovia Pharmaceuticals Inc
Nanomerics Ltd
Next Science Ltd
Nosopharm SAS
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Oryn Therapeutics
Pfizer Inc
Profem GmbH
Pulmocide Ltd
Riptide Bioscience Inc
Sano Chemicals Inc
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
Stadius Biopharma LLC
TGV Laboratories Inc
TGV Therapeutics
Toltec Pharmaceuticals LLC
Visterra Inc
Wellstat Vaccines LLC